Tiziana Life Sciences Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLSA research report →
Price Chart
About the company
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression.
- CEO
- Ivor R. Elrifi
- IPO
- 2018
- Employees
- 10
- HQ
- London, GB
Get TickerSpark's AI analysis on TLSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $70.63M
- P/E
- -4.07
- PEG
- -0.04
- P/S
- 0.00
- P/B
- 2.31
- EV/EBITDA
- 2.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -125.84%
- ROIC
- -41.20%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-21,132,000
- Net Income
- $-18,431,000-55.4%
- EPS
- $-0.32-45.5%
- OCF Growth
- -953.5%
- FCF Growth
- -942.3%
- 52W High
- $2.33
- 52W Low
- $0.76
- 50D MA
- $1.01
- 200D MA
- $1.26
- Beta
- 0.45
- RSI (14)
- 57
- Avg Volume
- 704.42K
No earnings-call transcripts are available for TLSA yet.
- Free Float
- 50.2%
- Shares Outstanding
- 63.63M
- Float Shares
- 31.92M
of shares held by institutions
34 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dauntless Investment Group, LLC | 1.16M | ▼ 1.00M |
| Mid-American Wealth Advisory Group, Inc. | 323.24K | ▲ 323.24K |
| Zhang Financial LLC | 125.95K | ▲ 14.05K |
| Goldman Sachs Group Inc | 119.24K | ▲ 43.58K |
| Citadel Advisors LLC | 80.22K | ▲ 45.13K |
| Colony Group, LLC | 79.36K | 0 |
| Geode Capital Management, LLC | 78.20K | 0 |
| Ubs Group AG | 72.88K | ▼ 22.82K |
| Hsbc Holdings PLC | 62.44K | 0 |
| Morgan Stanley | 53.66K | ▲ 1.50K |
| Hrt Financial LP | 45.59K | ▲ 45.59K |
| Ewa, LLC | 44.69K | ▼ 1.26K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 15, 26 | Elrifi Ivor | other | 1,050,000 |
| Aug 15, 26 | Elrifi Ivor | other | 1,050,000 |
| Jul 21, 26 | CERRONE GABRIELE M | buy | 42,357 |
| Jun 12, 26 | CERRONE GABRIELE M | buy | 15,000 |
| Aug 5, 26 | Elrifi Ivor | buy | 237,616 |
| Aug 4, 26 | Elrifi Ivor | buy | 83,807 |
| Aug 3, 26 | Elrifi Ivor | buy | 667,000 |
| Mar 18, 26 | Elrifi Ivor | other | 0 |
| Aug 15, 26 | Elrifi Ivor | other | 3,150,000 |
| Jul 21, 26 | CERRONE GABRIELE M | other | 42,357 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TLSA coverage
Recent articles, reports, and earnings notes.
No research on TLSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLSA report →Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
proactiveinvestors.com · Sep 30
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
proactiveinvestors.com · Sep 28
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
proactiveinvestors.com · Sep 21
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
proactiveinvestors.com · Sep 17
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
proactiveinvestors.com · Sep 3
Dow climbs as stocks rebound on earnings, falling Treasury yields
proactiveinvestors.com · Sep 3
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
proactiveinvestors.com · Aug 24
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
globenewswire.com · Aug 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.